Paragon Biosciences company Castle Creek Pharmaceuticals Receives Award from debra of America
Castle Creek Pharmaceuticals, a member of the Paragon Biosciences corporate family of companies, received the Partners in Progress Award at the 19th Annual debra of America (Systrophic Epidermolysis Bullosa Research Association of America) Benefit held October 26 in New York City.
The award recognizes the company's progress in developing an investigational topical diacerein 1% ointment (CCP-020) that is being evaluated for the treatment of epidermolysis bullosa simplex (EBS), a rare genetic condition that leads to extremely fragile skin resulting in mild to severe blistering, skin erosion and peeling of the epidermis layers in response to minor injury or friction. CCP-020 is engineered to block an important inflammatory signaling pathway associated with EBS, which could strengthen epidermal tissue and support healing. In a previously completed Phase 2 clinical trial that included 17 patients with EBS, 60 percent of patients treated with CCP-020 experienced at least a 40 percent reduction in blistering after four weeks
“Paragon Biosciences is committed to accelerating breakthrough medicines for patients, and we are proud to support Castle Creek Pharmaceuticals in its efforts to bring new treatment options to people with EBS,” said Jeff Aronin, chairman and CEO of Paragon Biosciences and co-founder of Castle Creek Pharmaceuticals (CCP). Paragon provides strategic counsel, an innovative operational model, and financial support for CCP. “We are also proud of the recognition by debra, an organization that is a true leader and advocate for the EBS community.”
"We are honored to be recognized by debra of America as we continue our efforts to develop a potentially disease-modifying therapy for people living with EBS, the most common form of epidermolysis bullosa," said Michael Derby, co-founder and chief executive officer at Castle Creek Pharmaceuticals. "Currently there are no treatment options that target the underlying cause of EBS, and we are focused on delivering new options to patients around the world who are fighting this debilitating condition."
About Paragon Biosciences
Paragon Biosciences, LLC improves the lives of patients suffering from debilitating diseases by building innovative biotechnology companies that bring important medicines to the market. Paragon’s portfolio companies are managed by healthcare industry leaders and biotech entrepreneurs committed to improving outcomes for patients. Paragon’s leadership and management team leverage their entrepreneurial experiences, and their expertise in securing 13 FDA drug approvals, to develop and finance biotechnology companies and accelerate their advancements. Paragon Biosciences is headquartered in Chicago, Illinois. For more information visit: www.paragonbiosci.com
About Castle Creek Pharmaceuticals
Castle Creek Pharmaceuticals (CCP), a member of the Paragon Biosciences corporate family, is a privately held biopharmaceutical company with a robust and diversified pipeline of late-stage products. The company business strategy is based on a demonstrated ability to identify and advance therapies backed by strong science with the potential to represent significant advances in the treatment of debilitating dermatologic and head and neck conditions with high unmet needs. For more information, please visit: www.castlecreekpharma.com